Sanjay J Mathew Selected Research

Ketamine

6/2022	A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
1/2022	Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.
1/2022	Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
1/2022	Does mismatch negativity have utility for NMDA receptor drug development in depression?
11/2021	A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice.
1/2021	Distinct trajectories of antidepressant response to intravenous ketamine.
1/2021	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
1/2021	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
5/2020	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
1/2020	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sanjay J Mathew Research Topics

Disease

32	Treatment-Resistant Depressive Disorder 06/2022 - 05/2008
19	Major Depressive Disorder (Major Depressive Disorders) 01/2022 - 05/2008
19	Anxiety Disorders (Anxiety Disorder) 11/2019 - 11/2002
10	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022 - 11/2006
8	Mood Disorders (Mood Disorder) 01/2022 - 09/2005
5	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 08/2008
5	Anhedonia 01/2021 - 05/2014
5	Depressive Disorder (Melancholia) 01/2021 - 08/2004
5	Mental Disorders (Mental Disorder) 04/2017 - 10/2003
4	Wounds and Injuries (Trauma) 09/2019 - 10/2003
3	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 09/2012 - 04/2009
2	Overweight 05/2020 - 01/2014
2	Mitochondrial Diseases (Mitochondrial Disease) 09/2012 - 04/2009
1	Parkinson Disease (Parkinson's Disease) 01/2022
1	Paranoid Disorders (Paranoia) 11/2021
1	Neuroinflammatory Diseases 01/2021
1	Obesity 05/2020
1	Cocaine-Related Disorders (Cocaine Addiction) 11/2019
1	Social Phobia 12/2017
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2017
1	Hypertrophy 01/2014
1	Traumatic Brain Injuries (Traumatic Brain Injury) 06/2013
1	Intractable Pain 03/2012
1	Alzheimer Disease (Alzheimer's Disease) 02/2012
1	Abdominal Obesity 07/2011
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2011
1	Syndrome (Syndromes) 03/2011
1	Schizophrenia (Dementia Praecox) 08/2010
1	Mental Fatigue 07/2010
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 09/2008
1	Pathologic Processes 08/2008

Drug/Important Bio-Agent (IBA)

36	Ketamine FDA LinkGeneric 06/2022 - 08/2008
20	Antidepressive Agents (Antidepressants)IBA 01/2022 - 05/2008
11	Glutamic Acid (Glutamate)FDA Link 12/2017 - 10/2003
9	Riluzole FDA LinkGeneric 11/2019 - 12/2005
6	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2021 - 02/2012
6	Corticotropin-Releasing HormoneIBA 01/2020 - 05/2008
6	Protons (Proton)IBA 07/2010 - 06/2004
5	NBI 77860IBA 01/2020 - 06/2014
5	Pharmaceutical PreparationsIBA 04/2017 - 12/2005
5	N-Methylaspartate (NMDA)IBA 03/2017 - 08/2008
5	N-acetylaspartate (N-acetyl aspartate)IBA 01/2014 - 06/2004
4	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 01/2020 - 05/2008
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2009
4	Anti-Anxiety Agents (Anxiolytics)IBA 04/2013 - 12/2005
3	EsketamineIBA 01/2022 - 03/2012
3	Anesthetics (Anesthetic Agents)IBA 01/2022 - 10/2012
3	AZD6765IBA 11/2021 - 03/2017
3	Serotonin (5 Hydroxytryptamine)IBA 01/2014 - 05/2008
3	Lactic Acid (Lactate)FDA LinkGeneric 09/2012 - 04/2009
2	Midazolam (Versed)FDA LinkGeneric 01/2019 - 01/2019
2	CRF receptor type 1IBA 11/2018 - 12/2017
2	Neuroprotective AgentsIBA 12/2017 - 06/2013
2	gamma-Aminobutyric Acid (GABA)IBA 08/2015 - 05/2009
2	Amino Acids FDA Link 08/2015 - 05/2009
2	Biological ProductsIBA 06/2014 - 11/2002
2	Glutathione (Reduced Glutathione)IBA 05/2014 - 09/2012
2	Anticonvulsants (Antiepileptic Drugs)IBA 02/2012 - 05/2008
2	NeuropeptidesIBA 07/2011 - 08/2008
2	Neurotransmitter Agents (Neurotransmitter)IBA 05/2009 - 08/2008
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2008 - 05/2008
2	CreatineIBA 06/2006 - 06/2004
1	Saline SolutionIBA 11/2021
1	ezogabine (retigabine)IBA 01/2021
1	VortioxetineIBA 01/2021
1	KynurenineIBA 01/2021
1	Potassium Channels (Potassium Channel)IBA 01/2021
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2021
1	Opioid Receptors (Opioid Receptor)IBA 01/2020
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2020
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 12/2018
1	6- (2- methyl- 4- (2- naphthyl)- 1,2,3,4- tetrahydroisoquinolin- 7- yl)pyridazin- 3- amineIBA 08/2015
1	AcidsIBA 01/2014
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2014
1	Excitatory Amino Acid AntagonistsIBA 09/2013
1	AntioxidantsIBA 09/2012
1	Phosphates (Orthophosphate)IBA 09/2012
1	Lamotrigine (Lamictal)FDA LinkGeneric 02/2012
1	Memantine (Namenda)FDA Link 02/2012
1	Indicators and Reagents (Reagents)IBA 07/2011
1	Insulin (Novolin)FDA Link 07/2011
1	vofopitantIBA 03/2011
1	Neurokinin-1 Receptor AntagonistsIBA 03/2011
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 08/2010
1	metabotropic glutamate receptor 2IBA 08/2010
1	naluzotanIBA 09/2008
1	Excitatory Amino AcidsIBA 08/2008
1	CatecholaminesIBA 08/2008
1	AMPA Receptors (AMPA Receptor)IBA 08/2008
1	Hormones (Hormone)IBA 05/2008

Therapy/Procedure

11	Therapeutics 01/2022 - 05/2008
4	Drug Therapy (Chemotherapy) 05/2008 - 12/2005
2	Deep Brain Stimulation 01/2022 - 05/2008
1	Duration of Therapy 11/2019
1	Aftercare (After-Treatment) 12/2017
1	Anesthesia 06/2013
1	Secondary Prevention 02/2010
1	Intravenous Administration 08/2008